Nancy Lurker - 21 Feb 2022 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
President & CEO, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
21 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 15:13:02 UTC
Previous filing
11 Feb 2022
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +13,717 +11% $0.000000 137,815 21 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -13,717 -50% $0.000000 13,718 21 Feb 2022 Common Stock 13,717 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units vest in three ratable annual installments beginning February 21, 2020.